Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.
J. van Meerbeeck (Edegem (Antwerp), Belgium), A. Dingemans (Rotterdam, Netherlands), L. Horn (Nashville, United States of America), V. Torri (Milano, Italy), J. Whisenant (Nashville, United States of America), H. Wakelee (Stanford, United States of America), S. Peters (Lausanne, Switzerland), M. Garassino (Milan, Italy), J. Cadranel (Paris, France), J. Chorostowska (Warsaw, Poland)
Source: Virtual Congress 2020 – COVID-19 clinical studies
Session: COVID-19 clinical studies
Session type: E-poster session
Number: 3584
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. van Meerbeeck (Edegem (Antwerp), Belgium), A. Dingemans (Rotterdam, Netherlands), L. Horn (Nashville, United States of America), V. Torri (Milano, Italy), J. Whisenant (Nashville, United States of America), H. Wakelee (Stanford, United States of America), S. Peters (Lausanne, Switzerland), M. Garassino (Milan, Italy), J. Cadranel (Paris, France), J. Chorostowska (Warsaw, Poland). Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.. 3584
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: